Sirtris Gains SIRT3 Licenses from Harvard

Xconomy Boston — 

Sirtris announced today that it has gained two exclusive licenses to Harvard University patents related to SIRT3, an enzyme believed to protect against cellular damage. The Cambridge, MA, biotech firm—which was acquired by British drug giant GlaxoSmithKline (NYSE: GSK) in June for $720 million—says the licenses cover assays that may identify SIRT3 activators for diseases of aging.